Appendix Table C14. KQ1 Outcome I. Hematologic response subgroup analysis: Darbepoetin versus control; no additional information

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study** | **Subgroups prospectively**  | **Darbepo n/N (%)** | **Control n/N (%)** | **p-value** |
| **Hedenus 2003** | **stratified for**  |  |  |  |
| lymphoma | 64% (55/86) | 13% (11/84) | <0.001 |
| myeloma | 56% (49/88) | 22% (20/86) | <0.001 |